References
- Department of Health and Human Services, Food and Drug Administration (2011), “Docket No. FDA 2010-N—0621 Proposal to Withdraw Approval for the Breast Cancer Indication for AVASTIN (Bevacizumab), Decision of the Commissioner.” https://www.fda.gov/media/82467/download
- Endocrinologic and Metabolic Drugs Advisory Committee (2015), “Meeting Materials.” https://wayback.archive-it.org/7993/20170722034435/ https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm 426278.htm
- Goodman, S. (2008), “A Dirty Dozen: Twelve P-Value Misconceptions,” Seminars in Hematology, 45, 135–140. DOI: 10.1053/j.seminhematol.2008.04.003.
- Ioannidis, J. P. A. (2019), “What Have We (Not) Learnt from Millions of Scientific Papers with P Values?,” The American Statistician, 73, 20–25. DOI: 10.1080/00031305.2018.1447512.
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (2016). “Merck Receives Complete Response Letter from the U.S. FDA for ZETIA[textregistered] (Ezetimibe) and VYTORIN[textregistered] (Ezetimibe and Simvastatin) [Press release].” Available at https://www.merck.com/news/merck-receives-complete-response-letter-from-the-u-s-fda-for-zetia-ezetimibe-and-vytorin-ezetimibe-and-simvastatin/ (accessed 06 Dec 2020)
- Trafimow, D. and Marks, M. (2015), “Editorial,” Basic and Applied Social Psychology, 37, 1, 1–2. DOI: 10.1080/01973533.2015.1012991.
- Wasserstein, R. L., and Lazar, N. A. (2016), “The ASA’s Statement on p-Values: Context, Process, and Purpose,” The American Statistician, 70, 129–133. DOI: 10.1080/00031305.2016.1154108.
- Wasserstein, R. L., Schirm, A. L., and Lazar, N. A. (2019), “Moving to a World Beyond ‘p < 0.05”’, The American Statistician, 73, 1–19.